News - Royalty Pharma
WEBAug 8, 2024 · Royalty Pharma Declares Third Quarter 2024 Dividend. Earnings. NEW YORK, NY, July 17, 2024 – The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of …
Royalty Pharma Announces $2.025 Billion Strategic Funding …
WEBJun 2, 2021 · NEW YORK, NY, and PLANEGG, GERMANY, June 2, 2021 – Royalty Pharma plc (Nasdaq: RPRX) and MorphoSys AG (FSE: MOR; Nasdaq: MOR) today announced a $2.025 billion strategic funding partnership as part of MorphoSys’ $1.7 billion acquisition of Constellation Pharmaceuticals.
Royalty Pharma Highlights Accomplishments and Provides …
WEBJan 8, 2024 · Royalty Pharma plc. 2023 Portfolio Receipts expected to be approximately $3,050 million, exceeding the upper end of guidance range. Announced transactions of $13 billion since 2020 expected to...
Royalty Pharma
WEBRoyalty Pharma Reports Second Quarter 2024 Results. Earnings. NEW YORK, NY, August 8, 2024 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2024 and raised full year 2024 guidance for Portfolio Receipts.
Royalty Pharma Announces Agreement to Purchase Up to $1.5 …
WEBNEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche’s Evrysdi for...
Royalty Pharma Reports Q4 and Full Year 2023 Results - Yahoo Finance
WEBFeb 15, 2024 · Royalty Pharma plc. Portfolio Receipts of $736 million in Q4 2023 and $3,049 million for FY 2023. Net cash provided by operating activities of $773 million in Q4 2023 and $2,988 million for FY...
Royalty Pharma Highlights Accomplishments and ... - Markets …
WEBNEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today provided an update on its business performance, including recent key accomplishments, and the full year 2023...
Royalty Pharma announces FDA approval milestone
WEB4 days ago · In other recent news, Royalty Pharma has been making significant strides in its business operations. The company reported a robust 12% increase in Q2 portfolio receipts, surpassing its high-single digit growth forecast. Additionally, Royalty Pharma invested $2 billion in new royalty transactions and acquired royalties on six therapies.
Royalty Pharma plc (RPRX) Stock Price & News - Google Finance
WEBGet the latest Royalty Pharma plc (RPRX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
WEBNEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it will acquire royalties and milestones on frexalimab owned by ImmuNext, Inc. (ImmuNext) for...